Renovaro End Period Cash Flow from 2010 to 2024
| RENB Stock | 0.61 0.09 17.31% |
End Period Cash Flow | First Reported 2011-06-30 | Previous Quarter 312.7 K | Current Value 220.6 K | Quarterly Volatility 5.8 M |
Check Renovaro Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Renovaro Biosciences' main balance sheet or income statement drivers, such as Interest Expense of 1.1 M, Selling General Administrative of 25.4 M or Other Operating Expenses of 85.7 M, as well as many indicators such as Price To Sales Ratio of 1.1 K, Dividend Yield of 0.0 or PTB Ratio of 1.19. Renovaro financial statements analysis is a perfect complement when working with Renovaro Biosciences Valuation or Volatility modules.
Renovaro | End Period Cash Flow |
Latest Renovaro Biosciences' End Period Cash Flow Growth Pattern
Below is the plot of the End Period Cash Flow of Renovaro Biosciences over the last few years. It is Renovaro Biosciences' End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Renovaro Biosciences' overall financial position and show how it may be relating to other accounts over time.
| End Period Cash Flow | 10 Years Trend |
|
End Period Cash Flow |
| Timeline |
Renovaro End Period Cash Flow Regression Statistics
| Arithmetic Mean | 5,047,448 | |
| Geometric Mean | 329,157 | |
| Coefficient Of Variation | 132.59 | |
| Mean Deviation | 5,490,502 | |
| Median | 1,874,480 | |
| Standard Deviation | 6,692,527 | |
| Sample Variance | 44.8T | |
| Range | 20.7M | |
| R-Value | 0.30 | |
| Mean Square Error | 43.8T | |
| R-Squared | 0.09 | |
| Significance | 0.27 | |
| Slope | 455,089 | |
| Total Sum of Squares | 627.1T |
Renovaro End Period Cash Flow History
About Renovaro Biosciences Financial Statements
Renovaro Biosciences stakeholders use historical fundamental indicators, such as Renovaro Biosciences' End Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Renovaro Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Renovaro Biosciences' assets and liabilities are reflected in the revenues and expenses on Renovaro Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Renovaro Biosciences. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| End Period Cash Flow | 220.5 K | 209.4 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Renovaro Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Renovaro Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Renovaro Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Renovaro Biosciences Stock:Check out the analysis of Renovaro Biosciences Correlation against competitors. For information on how to trade Renovaro Stock refer to our How to Trade Renovaro Stock guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Renovaro Biosciences. If investors know Renovaro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Renovaro Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.98) | Return On Assets (0.15) | Return On Equity (0.90) |
The market value of Renovaro Biosciences is measured differently than its book value, which is the value of Renovaro that is recorded on the company's balance sheet. Investors also form their own opinion of Renovaro Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Renovaro Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Renovaro Biosciences' market value can be influenced by many factors that don't directly affect Renovaro Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Renovaro Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Renovaro Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Renovaro Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.